IL58673A0 - Process for the isolation of membrane proteins neisseria meningitidis and vaccines containing same - Google Patents

Process for the isolation of membrane proteins neisseria meningitidis and vaccines containing same

Info

Publication number
IL58673A0
IL58673A0 IL58673A IL5867379A IL58673A0 IL 58673 A0 IL58673 A0 IL 58673A0 IL 58673 A IL58673 A IL 58673A IL 5867379 A IL5867379 A IL 5867379A IL 58673 A0 IL58673 A0 IL 58673A0
Authority
IL
Israel
Prior art keywords
isolation
membrane proteins
neisseria meningitidis
containing same
vaccines containing
Prior art date
Application number
IL58673A
Other versions
IL58673A (en
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of IL58673A0 publication Critical patent/IL58673A0/en
Publication of IL58673A publication Critical patent/IL58673A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Process for the isolation of membrane proteins from Neisseria meningitidis which comprises treating the organism with the aqueous solution of a detergent in a concentration of 0.1 to 2% w/v for 15 minutes to 24 hours, allowing the mixture to stand, optionally with agitation, separating the extract from the bacterial residue and optionally carrying out a further purification.
IL58673A 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same IL58673A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (en) 1978-11-11 1978-11-11 METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM

Publications (2)

Publication Number Publication Date
IL58673A0 true IL58673A0 (en) 1980-02-29
IL58673A IL58673A (en) 1983-02-23

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
IL58673A IL58673A (en) 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Country Status (9)

Country Link
EP (1) EP0011243B1 (en)
JP (1) JPS5566519A (en)
AT (1) ATE857T1 (en)
AU (1) AU533386B2 (en)
CA (1) CA1142083A (en)
DE (2) DE2848965A1 (en)
DK (1) DK154841C (en)
ES (1) ES485715A1 (en)
IL (1) IL58673A (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH074267B1 (en) * 1982-12-02 1995-01-25 Univ Rockefeller
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US8007815B1 (en) 1998-05-29 2011-08-30 Novartis Ag Combination meningitidis B/C vaccines
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN1416352B (en) 2000-01-17 2011-05-25 启龙股份公司 Outer membrane vesicle (OMV) vaccine comprising N. Meningitidis serogroup B outer membrane
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (en) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia MÃ0 / 00 METHOD OF OBTAINING COCLEAR STRUCTURES VACCINAL COMPOSITIONS AND ADJUSTS BASED ON COCLEAR STRUCTURES AND THEIR INTERMEDIARIES
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
JP5173194B2 (en) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP5275983B2 (en) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
EP2245048B1 (en) 2008-02-21 2014-12-31 Novartis AG Meningococcal fhbp polypeptides
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CN102300585A (en) 2008-12-17 2011-12-28 诺华有限公司 Meningococcal vaccines including hemoglobin receptor
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
AU2010288240B2 (en) 2009-08-27 2014-03-27 Novartis Ag Hybrid polypeptides including meningococcal fHBP sequences
CA2772103A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
JP2013521770A (en) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine composition
BR112012022896A2 (en) 2010-03-18 2018-03-27 Novartis Ag adjuvant vaccines for serogroup b meningococci
EA031379B1 (en) 2010-03-23 2018-12-28 Новартис Аг Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
ES2654613T3 (en) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococci
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
JP6324961B2 (en) 2012-09-06 2018-05-16 ノバルティス アーゲー Combination vaccine of serogroup B meningococcus and D / T / P
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
KR20200053531A (en) 2017-09-08 2020-05-18 에벨로 바이오사이언시즈, 인크. Bacterial extracellular vesicle
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CN112996538A (en) 2018-11-06 2021-06-18 葛兰素史密丝克莱恩生物有限公司 Immunogenic compositions
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
JPS6350332B2 (en) 1988-10-07
ES485715A1 (en) 1980-05-16
CA1142083A (en) 1983-03-01
DK475779A (en) 1980-05-12
DK154841C (en) 1989-06-05
ATE857T1 (en) 1982-04-15
DE2848965A1 (en) 1980-05-22
DE2962526D1 (en) 1982-05-27
AU5268279A (en) 1980-05-15
AU533386B2 (en) 1983-11-24
IL58673A (en) 1983-02-23
DK154841B (en) 1988-12-27
EP0011243A1 (en) 1980-05-28
EP0011243B1 (en) 1982-04-14
JPS5566519A (en) 1980-05-20

Similar Documents

Publication Publication Date Title
DE2962526D1 (en) Process for preparing membrane proteins from neisseria meningitidis and vaccines containing them
BG48934A3 (en) Method for biological preparing of amides
DE69423383D1 (en) Production and uses of LOS-reduced outer membrane proteins from gram-negative cocci
DE69224124D1 (en) Process for the preparation of dihomo-gamma-linolenic acid and the lipid contained therein
JPS5750925A (en) Preparation of pertussis toxoid
JPS6452726A (en) Method for removing endotoxin of pertussis, pertussis toxoid and production thereof
HUT44422A (en) Method and apparatus for improving the quality of roasted coffee
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
EP0607593A3 (en) Process for obtaining cell cultures with a higher content of autologous cytonines.
ATE72756T1 (en) PROCESS FOR PRODUCTION OF A BIOLOGICAL SUBSTANCE.
DE3265664D1 (en) Process for the production of a biochemical vaccine against salmonella fevers
AT384032B (en) METHOD FOR PRODUCING POLYDISPERSE NATIVE PSEUDOMONAS-FLAGELLA (H) -ANTIGENS (FAG)
YU183587A (en) Process for obtaining liquid ethanole extract of propolis
DE3366707D1 (en) Preparation of glucose dehydrogenase
JPS57122792A (en) Preparation of cholesterol oxidase
MA21382A1 (en) PROCESS FOR THE PREPARATION OF A JASMINE EXTRACT AND EXTRACT OBTAINED.
FR2429765A1 (en) ADSORPTION PROCESS AND AGENT FOR ISOLATING ENZYMES AND FOR PREPARING THEM IN PURE CONDITIONS
JPS5550890A (en) Preparation of n-acylneuraminic acid aldolase
DE3887713D1 (en) Phenanthridine derivatives, process for their preparation and agents for carrying out the process.
SU1515606A1 (en) Method of purification and isolation of sodium nitroprusside
JPS6410950A (en) Elimination of taste and odor of substance rich in amino acid
UA14449A1 (en) Process for preparation of pantocrine
JPS5682095A (en) Purification of fatty acid produced through fermentation process
JPS55102497A (en) Treatment of waste water containing thiocyanogen
JPS55102389A (en) Novel microorganism

Legal Events

Date Code Title Description
HP Change in proprietorship
KB Patent renewed